La catena delle opzioni mostra i dati chiave delle opzioni azionarie di FTC Solar a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per FTC Solar..

FTC Solar (NASDAQ:FTCI) Azioni, Catena delle Opzioni

FTC Solar

FTC Solar Inc is a provider of solar tracker systems, supported by proprietary software and value-added engineering services. The company's Solar tracker systems move solar panels throughout the day to maintain an optimal orientation relative to the sun, thereby increasing the amount of solar energy produced at a solar installation. It focuses on providing differentiated products, software, and services that maximize energy generation. The company has launched a new mounting solution to support the installation and use of U.S. manufactured thin-film modules by project owners. The only segment the company is engaged in is the Manufacturing and Servicing of Solar tracker systems.

FTC Solar Inc

WestPark Capital analyst Casey Ryan maintains Glimpse Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAR#NASDAQ">VRAR</a>) with a Buy and lowers the price target from $4.67 to $2.62.

News

Price Target

Analyst Ratings

VRAR

WestPark Capital Maintains Buy on Glimpse Group, Lowers Price Target to $2.62

WIIM

Woodside Energy shares are trading higher on possible continued strength after the company announced on Monday that it sold a 40% stake in the Louisiana LNG project for $5.7 billion to Stonepeak.

SCYNEXIS, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCYX#NASDAQ">SCYX</a>), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second-generation fungerp candidate SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) in Vienna, Austria being held from April 11-15, 2025.
SCY-247 is being developed to address systemic fungal diseases, with a key focus on invasive fungal infections where resistance to current limited treatment options is a significant concern. These presentations at ESCMID Global 2025 continue to build upon SCY-247's positive preclinical data illustrating its unique attributes in the fight against difficult-to-treat fungal infections, including its potent antifungal activity against multi drug-resistant fungi.

Biotech

General

SCYX

SCYNEXIS To Present Preclinical Data On Second Generation IV/Oral Fungerp SCY-247 At The European Society Of Clinical Microbiology And Infectious Diseases

Piper Sandler analyst Kashy Harrison initiates coverage on MasTec (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) with a Overweight rating and announces Price Target of $134.

Initiation

Piper Sandler Initiates Coverage On MasTec with Overweight Rating, Announces Price Target of $134

Bionano Genomics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNGO#NASDAQ">BNGO</a>) today announced a study published in The Journal of Molecular Diagnostics that describes a method for analysis of multiple myeloma (MM) by optical genome mapping (OGM). MM is one of the most common blood cancers, or hematologic malignancies, and is understood to be a difficult sample to analyze using traditional cytogenetics. Direct analysis of MM samples, by methods such as FISH or OGM, can be problematic because it is challenging to isolate enough cells with a known MM marker (CD138) on their surface, so-called CD138-positive cells. In this paper, researchers at Institute of Medical Genetics, Lille University Hospital, Lille, France, have described a method for OGM that can overcome the hurdle of limited sample quantity and can cut in half the effective CD138-positive cell requirement for analysis by OGM.
Key Findings and Takeaways &nbsp;
<ul>
<li>Mixing CD138-positive with CD138-negative cells from the same sample at a ratio of 1:1 can be sufficient to perform OGM. Since OGM typically requires 1 million cells, this finding suggests that as few as 0.5 million of the CD138-positive cells are sufficient &nbsp;</li>
<li>OGM reveals More Genetic Events: Achieving 93% (13/15) concordance with FISH, the current standard, OGM also uncovered more than 22 additional genetic variants that were previously undetected by FISH &nbsp;</li>
<li>OGM Streamlines the Analysis: Consolidating multiple assessments (KT and multiple FISH assays) into a single, comprehensive approach using OGM can be more efficient and maximize the value of scarce cell samples while simplifying laboratory workflows and reducing the need for separate, time-consuming tests 
<ul>
<li>OGM Improves Prognostic Risk Evaluation: By capturing both primary and novel potentially pathogenic variants, OGM provides a comprehensive genomic profile that can be used to support more precise prognostic risk stratification</li>
</ul>
</li>
</ul>

BNGO

Bionano Genomics' Optical Genome Mapping Method Enhances Multiple Myeloma Analysis, Reduces Cell Requirements, Uncovers Additional Genetic Variants, Streamlines Workflow, And Improves Prognostic Risk Evaluation, According To Study Published In The Journal Of Molecular Diagnostics

Lazard Asset Management has officially entered the U.S. ETF industry, launching its first three <a href="https://www.benzinga.com/etfs">actively managed ETFs</a> on Monday — Lazard Equity Megatrends ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THMZ#NASDAQ">THMZ</a>), Lazard Japanese Equity ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JPY#NASDAQ">JPY</a>), and Lazard Next Gen Technologies ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEKY#NASDAQ">TEKY</a>). With its stellar reputation for institutional-quality investment ideas and global research, Lazard is now putting some of its most persuasive concepts into the ETF wrapper—first ever in U.S. territory.
Also Read: <a href="https://www.benzinga.com/etfs/new-etfs/25/04/44672665/goldman-bets-on-india-boom-with-new-actively-managed-etf">Goldman Bets On India Boom With New Actively Managed ETF</a>
"This <a href="https://www.businesswire.com/news/home/20250407484516/en/Lazard-Asset-Management-Launches-its-First-Three-Active-ETFS-in-the-U.S.">launch </a>represents a significant step forward in making Lazard's sophisticated investment solutions accessible to more investors," said Rob Forsyth, global head of ETFs at Lazard. "We're launching high-conviction, alpha-seeking ETFs managed by expert, specialized teams."
THMZ is designed to harness the potential of seismic changes in the international economy—technological, demographic, or geopolitical. The fund has an expense ratio of 0.50% and invests in a diversified portfolio of themes associated with long-term megatrends.
JPY focuses on Japan&#8217;s changing economy as the nation shifts away from years of deflation towards a more inflationary, growth-oriented atmosphere. With a 0.60% expense ratio, JPY is managed actively by a bilingual team with decades of experience in local markets.
Focusing on the next wave of innovation, TEKY invests in international companies harnessing productivity from artificial intelligence, automation, and hardware innovations. The fund charges a 0.50% fee and relies on a proprietary valuation and screening model to locate high-potential tech stocks.
Lazard Asset Management CEO Evan Russo called the launch &#8220;a historic milestone,&#8221; indicating the firm&#8217;s commitment to addressing changing investor requirements with solutions combining research depth, active intelligence and ETF efficiency.
&#8220;For decades, Lazard has helped clients build stronger portfolios with world-class actively managed equity strategies,&#8221; said Jennifer Ryan, head of North America Distribution.
As macroeconomic uncertainty shakes the markets, active ETFs&#8217; flexibility—and Lazard&#8217;s experienced bench of experience behind its new funds—may provide investors with a new method of moving forward.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44670948/bitcoin-but-make-it-bounded-first-trust-launches-risk-buffered-crypto-etfs">New ETFs Offer Bitcoin Exposure With Built-In Safety Nets</a></li>
</ul>
Photo: Shutterstock

New ETFs

ETFs

TEKY

THMZ

Lazard Debuts First US ETFs, Betting On Megatrends, Japan And AI

WestPark Capital analyst Casey Ryan reiterates Ideal Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPWR#NASDAQ">IPWR</a>) from Hold to Hold.

Reiteration

IPWR

WestPark Capital Reiterates Hold on Ideal Powerto Hold

Macro Economic Events

Econ #s

Economics

USA Redbook (YoY) 7.2%; 4.8% Prior

Oppenheimer analyst Ken Wong maintains Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) with a Outperform and lowers the price target from $350 to $300.

ADSK

Oppenheimer Maintains Outperform on Autodesk, Lowers Price Target to $300

Nu Holdings shares are trading higher after JP Morgan upgraded the stock from Neutral to Overweight.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Jefferies analyst Peter Abramowitz initiated coverage on Sun Communities, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUI#NYSE">SUI</a>) with a Buy rating and announced a price target of $150. Sun Communities shares closed at $119.23 on Monday. <a href="https://www.benzinga.com/quote/sui/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. analyst Yi Chen initiated coverage on VolitionRx Limited (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) with a Buy rating and announced a price target of $2.5. VolitionRX shares closed at $0.4999 on Monday. <a href="https://www.benzinga.com/quote/vnrx/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Hong Zhang initiated coverage on Weyerhaeuser Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WY#NYSE">WY</a>) with an Overweight rating and announced a price target of $31. Weyerhaeuser shares closed at $25.48 on Monday. <a href="https://www.benzinga.com/quote/wy/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Leerink Partners analyst Faisal Khurshid initiated coverage on Spyre Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRE#NASDAQ">SYRE</a>) with an Outperform rating and announced a price target of $45. Spyre Therapeutics shares closed at $12.39 on Monday. <a href="https://www.benzinga.com/quote/syre/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>William Blair analyst Lachlan Brown initiated coverage on Ocular Therapeutix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) with an Outperform rating. Ocular Therapeutix shares closed at $6.30 on Monday.  <a href="https://www.benzinga.com/quote/OCUL/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying WY stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="589" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08085224/image-37-1024x589.png" alt="" class="wp-image-861893" style="width:536px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08085224/image-37-1024x589.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08085224/image-37-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08085224/image-37-768x441.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08085224/image-37.png 1082w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44678688/dow-falls-for-3rd-session-amid-trumps-tariff-threats-as-apple-tesla-decline-greed-index-remains-in-extreme-fear-zone">Dow Falls For 3rd Session Amid Trump&#8217;s Tariff Threats As Apple, Tesla Decline: Greed Index Remains In &#8216;Extreme Fear&#8217; Zone</a></li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

Trading Ideas

OCUL

SYRE

VNRX

This Weyerhaeuser Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

B of A Securities analyst Robert Ohmes maintains Dollar Tree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) with a Underperform and lowers the price target from $75 to $70.

DLTR

B of A Securities Maintains Underperform on Dollar Tree, Lowers Price Target to $70

YYGH

YY Group Holding Limited 2024 Revenue Reached $41.1M

SELLAS Life Sciences Group Announced Cohort 3 Data From Ongoing Phase 2 Trial Of SLS009 In r/r AML

Needham analyst Serge Belanger reiterates Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) with a Buy and maintains $4 price target.

CLSD

Needham Reiterates Buy on Clearside Biomedical, Maintains $4 Price Target

Needham analyst Serge Belanger reiterates NewAmsterdam Pharma Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAMS#NASDAQ">NAMS</a>) with a Buy and maintains $42 price target.

NAMS

Needham Reiterates Buy on NewAmsterdam Pharma Co, Maintains $42 Price Target

<a href="https://www.benzinga.com/real-estate">Real estate investing</a> is no longer about buildings alone—and Long Pond Capital appears to understand that.
The company just debuted its <a href="https://www.benzinga.com/etfs">first ETF</a>, the Long Pond Real Estate Select ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPRE#NYSE">LPRE</a>), and it&#8217;s taking a more expansive view of what it means to invest in real estate. Instead of concentrating on traditional real estate investment trusts (REITs), LPRE is targeting the whole &#8220;greater real estate economy,&#8221; as outlined in its prospectus.
So what does that look like in action?
Also Read: <a href="https://www.benzinga.com/etfs/new-etfs/25/04/44672665/goldman-bets-on-india-boom-with-new-actively-managed-etf">Goldman Bets On India Boom With New Actively Managed ETF</a>
The fund focuses on mid- to large-cap stocks that earn most of their income from real estate-related businesses. That does mean REITs, naturally, but it also means real estate common stocks and firms serving the industry, even if they don&#8217;t fit neatly into the real estate category. That might include infrastructure companies, service companies, or even technology companies with heavy real estate exposure.
LPRE intends to maintain a fairly focused portfolio of around 30 companies at any given moment. But it&#8217;s not merely taking names from a list. The portfolio managers engage in a deep-dive, fundamentals-driven approach, scrutinizing each company&#8217;s financial well-being, management, and potential for long-term value.
In the background, Exchange Traded Concepts serves as the advisor to the fund, with Long Pond Capital providing the subadviser services. A team of veteran managers, consisting of John Khoury, Andrew Serowik, Todd Alberico, Gabriel Tan, and Brian Cooper, oversees the fund. LPRE has an expense ratio of 1.10%.
For investors, real estate ETFs have been a standard choice for diversification—providing exposure to the real estate market without the hassle or expense of actually owning property. LPRE does the same but with a twist by expanding its focus beyond standard REIT-biased strategies.
As the real estate space continues to mature, LPRE is wagering that a wider lens might reveal new opportunities for long-term growth.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44670948/bitcoin-but-make-it-bounded-first-trust-launches-risk-buffered-crypto-etfs">New ETFs Offer Bitcoin Exposure With Built-In Safety Nets</a></li>
</ul>
Image: Shutterstock

REIT

Real Estate

LPRE

LPRE ETF Looks Past REITs To Capture 'Greater' Real Estate Economy

Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) has been an unlikely standout in a turbulent tech year, but <a href="https://www.benzinga.com/quote/meta/news" target="_blank" rel="noopener">the chart suggests</a> the party might be coming to an end.
Despite outperforming its Mag 7 peers year-to-date, Meta is now down 13.85% YTD, slipping 13.67% in the last month alone.
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44680723/despite-tariff-turmoil-bitcoin-outperforms-magnificent-7-stocks-in-2025-records-smaller-losses-than-nvidia-tesla-apple">Despite Tariff Turmoil, Bitcoin Outperforms &#8216;Magnificent 7&#8217; Stocks In 2025 — Records Smaller Losses Than Nvidia, Tesla, Apple</a>
"Meta's current valuation is still reasonably priced relative to most of its Mag Seven counterparts, which might explain why the stock has shown some relative strength," said Ed Egilinsky, managing director at Direxion, in an exclusive interview with Benzinga.
But with the stock plunging nearly 10% over the past five sessions and rebounding just +2.28% early Tuesday, traders are watching closely for signs of a turning tide.
<h2 class="wp-block-heading">Meta Stock Technicals Flash A Warning</h2>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0408"><img loading="lazy" decoding="async" width="629" height="491" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08064356/Screenshot-2025-04-08-at-4.13.43-PM.png" alt="" class="wp-image-861621" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08064356/Screenshot-2025-04-08-at-4.13.43-PM.png 629w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08064356/Screenshot-2025-04-08-at-4.13.43-PM-300x234.png 300w" sizes="(max-width: 629px) 100vw, 629px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0408">Chart created using Benzinga Pro</a>
Meta stock technicals look grim. Trading at $516.25, the stock is below its eight, 20, 50, and 200-day simple moving averages (SMAs)—all flashing bearish signals. Its eight-day SMA stands at $559.78 and the 50-day SMA is at a distant $643.73.
The MACD (moving average convergence/divergence) indicator is a steep negative 28.60, and the RSI (relative strength index) is just 29.80 &#8211; suggesting that Meta stock is oversold but struggling to regain momentum.
<h2 class="wp-block-heading">Tariffs &amp; Tension Ahead Of Earnings</h2>
Investor sentiment was initially unfazed by tariff talk, but that changed fast. "Initially, many investors were viewing the tariff risks to Meta stock as nominal. However, with the announced tariffs&#8230;many investors have reassessed the potential impact it might have on Meta's global advertising revenue, specifically within China," Egilinsky said.
Meta reports earnings on April 30, a make-or-break moment that could either confirm the bearish trend or offer a catalyst for a rebound.
Traders betting on a bounce or bracing for more downside are carefully eyeing those short-term technicals.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/04/44680269/elon-musks-net-worth-dives-below-300-billion-for-the-first-time-since-november-amid-tesla-attacks-and-tariff-woes">Elon Musk&#8217;s Net Worth Dives Below $300 Billion For The First Time Since November Amid Tesla Attacks And Tariff Woes</a></li>
</ul>
Photo: Shutterstock

Technicals

Exclusives

Tech

Interview

EXCLUSIVE: Meta's Still The Mag 7 Standout, Says Expert - But Can It Hold On?

B of A Securities analyst Julien Dumoulin-Smith maintains First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) with a Buy and lowers the price target from $236 to $215.

FSLR

B of A Securities Maintains Buy on First Solar, Lowers Price Target to $215

OTLK

Outlook Therapeutics Announced FDA Acknowledged Receipt Of Resubmission Of Biologics License Application For ONS-5010

Press Releases

FTC Solar to Supply Approximately 1GW of Projects for Sandhills Energy

Contracts

FTC Solar Announces 1GW Tracker Supply Agreement with Dunlieh Energy

FTC Solar to Announce Third Quarter Financial Results Tuesday, November 12, 2024

Earnings

FTC Solar Announces Third Quarter 2024 Financial Results

FTC Solar Announces Reverse Stock Split

FTC Solar Announces Closing of Promissory Note Private Placement

Management

FTC Solar Appoints Kent James Chief Commercial Officer

FTC Solar to Announce Fourth Quarter and Full Year 2024 Financial Results Monday, March 31, 2025

FTC Solar Announces Fourth Quarter 2024 Financial Results

FTC Solar Introduces Revolutionary Dual-Row Configuration for 1P Pioneer Tracker™: Industry's Highest East-West Slope Tolerance for a linked tracker

FTCI

Asia Pacific Wire & Cable Corporation Limited - Common shares, Par value .01 per share

Comments

FTC Solar

FTC Solar (FTCI) Opzioni

FTC Solar (NASDAQ:FTCI) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO